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Abstract
Although historically considered a disease primarily affecting the white matter of the central nervous system,
recent pathological and imaging studies have established that cortical demyelination is common in multiple
sclerosis and more extensive than previously appreciated. Subpial, intracortical and leukocortical lesions are the
three cortical lesion types described in the cerebral and cerebellar cortices of patients with multiple sclerosis.
Cortical demyelination may be the pathological substrate of progression, and an important pathologic correlate of
irreversible disability, epilepsy and cognitive impairment. Cortical lesions of chronic progressive multiple sclerosis
patients are characterized by a dominant effector cell population of microglia, by the absence of macrophagic and
leukocytic inflammatory infiltrates, and may be driven in part by organized meningeal inflammatory infiltrates.
Cortical demyelination is also present and common in early MS, is topographically associated with prominent
meningeal inflammation and may even precede the appearance of classic white matter plaques in some MS
patients. However, the pathology of early cortical lesions is different than that of chronic MS in the sense that early
cortical lesions are highly inflammatory, suggesting that neurodegeneration in MS occurs on an inflammatory
background and raising interesting questions regarding the role of cortical demyelination and meningeal
inflammation in initiating and perpetuating the disease process in early MS.
Review
Multiple sclerosis (MS), a chronic idiopathic inflamma-
tory demyelinating disease, is the most common cause
of nontraumatic disability in young adults [1]. Focal
areas of demyelination and relative axonal preservation
on a background of inflammation and gliosis represent
the pathological features of MS [2,3].
Historically, MS has been considered a disease primar-
ily affecting the CNS white matter and its pathological
features were beautifully described and illustrated by
Professor Jean-Martin Charcot, an illustrious French
neurologist and pathologist, in his famous “Lectures on
t h eD i s e a s e so ft h eN e r v o u sS y s t e m ” delivered at the
Salpêtrière in 1868 [2]. In lecture VI, entitled “Dissemi-
nated Sclerosis. Pathological Anatomy”,b e s i d e s
acknowledging the involvement of the cerebral and cere-
bellar white matter, deep grey matter, brainstem, and
spinal cord white and grey matter, Professor Charcot
also pointed to the existence of the cortical
demyelinated lesions: “...the patches are very rarely
f o u n do nt h eg r e ys u b s t a n c eo ft h ec o n v o l u t i o n s “ [2].
Because of their poor visualization when using conven-
tional histological methods [4], the study of cortical
lesions has largely been disregarded although early post-
Charcot neuropathological studies have increasingly
recognized the involvement of grey matter in MS [5,6].
While white matter lesion load has been able to
explain only part of the clinical deficits seen in MS
patients, cognitive impairment and seizures could be
better explained by pathological processes affecting the
grey matter [7-14]. It has also been shown that immu-
nohistochemical techniques are superior to classical
myelin histochemical staining methods (luxol fast blue)
for detecting cortical demyelinating lesions [4]. More-
over, even among immunohistochemical markers for
various myelin proteins, the use of antibodies specific to
major myelin proteins is superior to antibodies against
minor myelin proteins at detecting cortical demyelina-
tion. Therefore, armed with a clinical rationale and with
the means to pathologically detect cortical lesions, the
last decade has witnessed a surge in the interest allo-
cated to cortical demyelination in MS and represented a
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imaging and clinical studies on MS cortical pathology.
Recent imaging and pathological studies have indeed
confirmed that cortical demyelination is common in MS
and more extensive than previously appreciated
[4,15-21].
Classification
The first pathological classification of cortical lesions
has been proposed by Kidd et al. [17]. Seven cortical
demyelinated lesion types have been described based on
their location relative to the venous supply of the cere-
bral cortex. Type 1 lesions affect both the deep grey
matter layers and the subadjacent white matter. Type 2
lesions involve all cortical layers without affecting the
underlying white matter. Type 3 lesions involve only the
upper cortical layers. Type 4 lesions only involve the
subcortical U fibers. Type 5 lesions affect all grey matter
layers as well as the subcortical white matter. Type 6
lesions are small demyelinated lesion that can occur in
any part of the cortex. Type 7 lesions extend on both
banks of a gyrus with or without involvement of the
subcortical white matter. The majority of lesions (types
1, 4 and 5) arise within the territory of the principal
vein [17], whose course begins in the white matter and
passes through the cortex [22]. The remaining lesions
are located in the territory drained by its branches or in
the territory of the superficial veins [17].
A simpler classification has been proposed by Peterson
et al. and is based on the location of the cortical demye-
linated lesions within the layers of the cortical grey mat-
ter [4,16]. Studying autopsy material from patients with
chronic MS, the authors described four cortical lesion
types [4,16]. Type I lesions, also called leukocortical
lesions, involve the deeper layers of the grey matter as
well as the subadjacent white matter at the grey/white
matter junction with sparing of the superficial layers of
the cortex (Figure 1A). Type II lesions, or intracortical
lesions, are small demyelinated lesions centered on
blood vessels and confined within the cortex, with spar-
ing of both the superficial cortex and the white matter
(Figure 1B). Type III lesions extend from the pial sur-
face into the cortex, most often reaching the cortical
layers 3 or 4 (Figure 1C). Type IV lesions extend to the
entire width of the cortex without entering the subcorti-
cal white matter (Figure 1D) [4,16]. Type III and IV
lesions are referred to as subpial lesions and can involve
multiple adjacent gyri (general subpial demyelination)
[4,16]. Subpial, intracortical and leukocortical demyeli-
nating lesions have also been described in the cerebellar
cortex and hippocampus [23-26].
While the latter classification is widely accepted cur-
rently, there are cortical demyelinated lesions that are
unaccounted for by the present classification,
highlighting the still incomplete understanding of their
origin and evolution. We consider lesions affecting all 6
cortical layers with only marginal involvement of the
white matter as subpial, rather than leukocortical
demyelinated lesions [27]. Their subpial nature is sup-
ported by the centrifugal extension of the lesion from
the pial surface into the cortex; the involvement of all
cortical layers; the vast area of demyelination within the
cortex with only limited involvement of the subcortical
white matter; and the fact that the center of the lesion
is in the grey and not in the white matter [27] as most
often reported for leukocortical lesions [4,16]. How to
classify a cortical lesion involving the whole grey matter
width as well as a considerable region of the subadjacent
white matter becomes even more complicated, and, the-
oretically, any of the following possibilities is feasible: a
subpial lesion that extends into the white matter; a
white matter lesions that extends into the cortex even-
tually reaching the pia; the coalescence of a subpial
lesion with a white matter lesion; or the coalescence of
a subpial lesion with a leukocortical lesion. While some-
times there are pathological cues that help in inferring
the evolution of such a lesion [28], it is clear in most
cases that its dynamics cannot be deduced from only
one snapshot in the lesion’s development that pathology
offers.
The Pathology of Cortical Demyelination
and Meningeal Inflammation in Chronic
Progressive MS
The most extensive cortical demyelination has been
detected in the cingulate gyrus (Figure 2A), frontal (Fig-
ure 2B), temporal, insular and cerebellar cortices, as well
as in the hippocampi (Figure 2C) of patients with pro-
gressive MS, while the paracentral lobule and the occipi-
tal lobe are less frequently affected but not spared
(Figure 2D) [16,18,23-26,29]. Subpial demyelination pre-
ferentially involves the sulci suggesting that it may be
induced by stagnant cerebrospinal fluid mediators [4].
Pathological studies have shown that cortical demyelina-
tion is prominent and extensive in primary progressive
and secondary progressive MS, and in MS patients with
cognitive deficits, suggesting it may be the pathological
substrate of progression, and an important pathologic
correlate of irreversible disability and cognitive impair-
ment [16,18,25].
Similarly to white matter lesions, cortical demyelinated
lesions studied in autopsy material from chronic MS
patients are well-demarcated, and show oligodendrocyte,
axonal and synaptic loss [4,15,16,20]. However, other
studies described normal synaptic densities in cortical
lesions [25,30].
In several other aspects, the pathology of cortical
lesions has been reported to be fundamentally different,
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than white matter lesions. Purely cortical lesions report-
edly lack the lymphocytic and macrophagic inflamma-
tory infiltrates, complement deposition and blood-brain
barrier breakdown [4,15,16]. Leukocortical lesions are
more inflammatory than subpial and intracortical
lesions, but less so than lesions in the white matter
[4,15,16,25,30]. The majority of phagocytic cells in corti-
cal lesions have the morphology of activated ramified
microglia that appear in close apposition to neurites and
neuronal cell bodies [4,15,16,25,30]. Neurons are also
damaged as evidenced by neuronal atrophy and apopto-
sis, and a mild to moderate reduction of neuronal densi-
ties in the demyelinated MS cortex [4,16,20,30].
Meningeal inflammatory infiltrates have been exten-
sively characterized in late-stage progressive MS. They
are topographically associated with subpial lesions,
resemble lymphoid follicular structures, predominate
among patients with secondary progressive MS [31,32]
and are immunoreactive for Epstein-Barr virus [33].
However, the identification of Epstein-Barr virus infec-
tion of meningeal B-cells and its potential role in the
pathogenesis of MS remains controversial as these find-
ings have not been confirmed by other studies [34,35].
Furthermore, ectopic B-cell follicle-like structures, topo-
graphically associated with subpial lesions, are located in
the deep sulci of the temporal, cingulate, insula and
frontal cortices of secondary progressive MS patients
with accelerated clinical course [36]. Therefore, menin-
geal inflammatory aggregates are believed to contribute
to both cortical demyelination and MS disease
progression.
Thus, according to studies that have analyzed cortical
pathology in autopsy material from chronic MS patients,
cortical demyelination is devoid of inflammatory
lymphocytes and macrophages and is driven in part by
organized meningeal inflammatory infiltrates
[4,15,16,31,36]. Corroborated with evidence for neuronal
degeneration and glial loss [4,16,20,30], this has led to
the suggestion that neurodegeneration in MS proceeds
independent of inflammation. However, we have to
stress again upon the fact that these studies have relied
on post-mortem tissue analysis from MS patients with
long-standing, end-stage disease, and that virtually
Figure 1 Cortical demyelinated lesion types. (A) Leukocortical lesion (PLP, scale bar = 100 μm); (B) Intracortical lesion (PLP, scale bar = 500
μm); (C) Subpial lesion affecting the superficial cortical layers (PLP, scale bar = 250 μm); (D) Subpial lesion involving all cortical layers without
affecting the white matter (PLP, scale bar = 500 μm).
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demyelination in early MS.
The Pathology of Cortical Demyelination and
Meningeal Inflammation in Early MS
MS may involve the cortex either as classically demyeli-
nated plaques or as neuronal loss and atrophy following
retrograde degeneration from white matter lesions [6].
Although cortical lesions could occur secondary to
w h i t em a t t e rd a m a g e[ 3 7 , 3 8 ] , recent histopathological
studies have shown that cortical demyelination may
occur spatially removed from and without obvious ana-
tomical relationships to the white matter pathology [39].
Therefore, it is plausible that the cortex could represent
an important early and/or initial target of the MS dis-
ease process.
MRI has confirmed that cortical lesions and atrophy
are already present in early disease [19,40,41] and
become more prominent during progressive MS [7,42].
Thirty seven percent of patients with clinically isolated
syndrome show the presence of cortical lesions [43].
Cortical lesions are more numerous and cortical atro-
phy is more pronounced in patients with relapsing
remitting MS and cognitive deficits than patients with
relapsing remitting MS who do not have cognitive def-
icits [44]. Relapsing remitting MS patients with epi-
l e p s ya l s oh a v em o r es e v e r ea n dr a p i d l ye v o l v i n g
cortical lesion load and atrophy compared with relap-
sing remitting MS patients without epilepsy [45]. Also,
a longitudinal MRS study of cortex in relapsing remit-
ting MS has showed periodic peaks consistent with
myelin breakdown [46], and increased apparent diffu-
sion coefficients in normal appearing cortex, probably
reflecting focal and diffuse cortical damage [40]. Thus,
cortical demyelination is already present and common
in early MS, and may represent the pathological sub-
strate of cognitive impairment and epilepsy in relap-
sing remitting MS. Furthermore, MRI evidence of MS
cortical onset [41] has been published supporting the
hypothesis that cortical demyelination could even
represent the earliest pathological event in some MS
patients.
Figure 2 Non-inflammatory cortical demyelination is prominent in chronic MS. (A) Cortical demyelination in the cingulate gyrus (PLP, scale
bar = 5 mm); (B) Cortical demyelination in the frontal lobe (PLP, scale bar = 5 mm); (C) Cortical demyelination in the hippocampus (PLP, scale
bar = 2.5 mm); (D) Although the occipital lobe is less frequently affected, cortical demyelination can be very extensive in the occipital lobe of
some MS patients (PLP, scale bar = 5 mm).
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MS has indeed revealed that cortical demyelination and
blood-brain barrier damage also occur early in disease
( F i g u r e3 A - C ) ,e v e np r e c e d i n gt h ea p p e a r a n c eo fc l a s s i c
white matter plaques in some MS patients [21,27]. The
majority of all cortical lesion types in early MS are
highly inflammatory with intense myelin-laden macro-
phages (Figure 3D) and lymphocytic (Figure 3E-F) infil-
trates similarly to active white matter lesions [21,27].
Lymphocytes, macrophages and microglia are seen in
Figure 3 Inflammatory cortical demyelination is present and common in early MS. (A-C) Tissue obtained at autopsy form patients with
acute MS: (A) Prominent cortical demyelination in the neocortex with the presence of all cortical lesion types: extensive subpial demyelination,
intracortical demyelination (white arrow) and leukocortical demyelination (black arrow) (PLP, scale bar = 2.5 mm); (B) Cortical demyelination in the
hippocampus (PLP, scale bar = 2.5 mm); (C) Subpial cerebellar demyelinated lesion (PLP, scale bar = 500 μm). (D-E) Inflammatory cortical
demyelination in the cortex from biopsied patients: (D) Demyelinated cortex (arrowhead indicates a neuron) infiltrated by myelin-laden macrophages
consistent with active demyelination (arrows) (PLP; scale bar = 50 μm); (E) Perivascular inflammation, degenerating neurons (arrowheads) scattered
among normal-looking neurons (black arrows) and reactive astrocytes (white arrows) are present in cortical lesions in early MS (HE, scale bar = 50 μm);
(F) Lymphocytic perivascular and diffuse inflammatory infiltrates in the demyelinated cortex (CD3, scale bar = 250 μm).
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direct role of the inflammatory cells in neuronal damage
(Figure 3E) [21,27]. All these differences can be
explained by different lesional stages and suggest that
the non-inflammatory character of chronic cortical
demyelination may relate to long intervals between
lesion formation and autopsy [47]. Similarly to chronic
plaques, cortical lesions in early MS also show loss of
oligodendrocyte, and axonal and neuronal injury (Figure
3E) most likely the result of the acute inflammatory
insult [21,27]. The presence of inflammatory cortical
demyelination in early MS argues against a primary neu-
rodegenerative process at this stage of disease. A
recently developed rodent EAE model for cortical
demyelination demonstrated that cortical inflammation
is an early, transient and rapidly resolving phenomenon
[48]. Therefore, the rapid resolution of cortical inflam-
mation may in part explain these apparent discordant
findings with respect to the presence of inflammation in
early versus chronic cortical demyelinating lesions. The
fact that cortical demyelination is more extensive in pro-
gressive than early MS could be explained by the extre-
mely fast and efficient remyelination of cortical lesions
in early disease stages [49].
Meningeal inflammation is prominent not only in
chronic MS, but also in early MS. Both focal perivas-
cular meningeal inflammation and diffuse meningeal
inflammation are topographically, significantly and
strongly associated with cortical lesions in early MS
(Figure 4) [21]. By analogy with observations made in
experimental autoimmune encephalomyelitis [50-52], it
is plausible that early meningeal inflammation in MS,
Figure 4 Meningeal inflammation is topographically associated with cortical demyelination in early MS (autopsy tissue from patients
with acute MS). (A) Subpial lesion overlaid by a perivascular meningeal inflammatory infiltrate (PLP, scale bar = 500 μm); (B) Higher magnification
of (A) (PLP, scale bar = 250 μm); (C) Higher magnification of the perivascular meningeal infiltrate (HE, scale bar = 50 μm); (D) Intracortical lesion
overlaid by perivascular meningeal inflammation (PLP, scale bar = 250 μm); (E) Higher magnification of the perivascular meningeal infiltrate (PLP,
scale bar = 50 μm); (F) Macrophages are components of the perivascular meningeal infiltrate (KiM1P, scale bar = 100 μm); (G) Large subpial lesion
underlying meningeal inflammation (PLP, scale bar = 500 μm); (H) Higher magnification of the meningeal inflammation (PLP, scale bar = 100 μm);
(I) Myelin-laden macrophages are found in the meninges of patients with acute MS (PLP, scale bar = 20 μm).
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the subarachnoid space, could not only drive cortical
demyelination, but also set the stage for subsequent
subcortical white matter inflammation and demyelina-
tion [21].
Conclusion
Although very prominent in chronic progressive MS
[4,15,16,18], pathological and MRI evidence show that
cortical demyelinated lesions are also present and com-
mon in early MS, and may be driven by meningeal
inflammation [18,21,27,41,43-45]. Their inflammatory
character suggests that neurodegeneration in MS runs
on a background of inflammation [21,27]. Moreover,
inflammatory cortical lesions may precede the appear-
ance of classic white matter plaques at MS onset
emphasizing the importance of considering demyelinat-
ing disease in the differential diagnosis of patients pre-
senting with a solitary cortical enhancing lesion on
MRI [27,41].
Although pathology has played a major role in under-
standing the pathophysiology of cortical demyelination,
it is clear that the evolution of cortical lesions cannot be
entirely understood from only one snapshot in the
lesion’s development that pathology offers. Conventional
MRI techniques are not sensitive to detect intracortical
and subpial lesions, but more recent imaging protocols
using double inversion recovery and high field MRI
have substantially improved their in vivo detection
[53-57], and, without a doubt, will play, alongside
pathology, a major role in fully elucidating the contribu-
tion of cortical demyelination to MS pathogenesis.
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